Hematopoiesis News Volume 12.36 | Sep 14 2021

    By
    Justin.choi
    -
    0
    37







    2021-09-14 | HN 12.36


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.36 – 14 September, 2021
    TOP STORY

    HLF Expression Defines the Human Hematopoietic Stem Cell State

    To identify genes with the most selective expression in human HSCs, researchers profiled population- and single-cell transcriptomes of un-expanded and ex vivo cultured cord blood-derived hematopoietic stem and progenitor cells as well as peripheral blood, adult bone marrow, and fetal liver.
    [Blood]

    Abstract

    Subscribe to the Stem Cell Podcast newsletter for a chance to win a bluetooth speaker.
    PUBLICATIONSRanked by the impact factor of the journal

    Single-Cell Profiling of Human Bone Marrow Progenitors Reveals Mechanisms of Failing Erythropoiesis in Diamond-Blackfan Anemia

    The authors investigated how mutations in either ribosomal protein large or ribosomal protein small subunit genes selectively affected erythroid progenitor development and clinical phenotypes in Diamond-Blackfan anemia, a rare ribosomopathy with limited therapeutic options.
    [Science Translational Medicine]

    Full Article

    Single-Cell Transcriptome of Early Hematopoiesis Guides Arterial Endothelial-Enhanced Functional T Cell Generation from Human PSCs

    Scientists performed extensive single-cell transcriptomic analyses to map fate choices and gene expression patterns during hematopoietic differentiation of human PSCs and showed that oxidative metabolism was dysregulated during in vitro directed differentiation.
    [Science Advances]

    Full Article

    Remodeling of Metabolism and Inflammation by Exercise Ameliorates Tumor-Associated Anemia

    Investigators demonstrated that reduced red blood cell (RBC) survival rather than altered erythropoiesis was driving the development of anemia. The tumor-induced inflammatory and metabolic remodeling affected RBC integrity and augmented splenic phagocyte activity promoting erythrophagocytosis.
    [Science Advances]

    Full Article

    The Ubiquitin Ligase RNF5 Determines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

    RNF5 inhibition decreased acute myeloid leukemia cell growth in culture, in patient-derived xenograft samples and in vivo, and delayed development of MLL-AF9–driven leukemogenesis in mice, prolonging their survival.
    [Nature Communications]

    Full Article

    Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma

    Using BRAF-mutated myeloma as a model for resistance to precision medicine, the authors investigated if BRAF-mutated cancer cells had the ability to ensure their survival by rapidly adapting to BRAF inhibitor treatment.
    [Clinical Cancer Research]

    Abstract

    Insufficiency of Non-Canonical PRC1 Synergizes with JAK2V617F in the Development of Myelofibrosis

    Researchers investigated the impact of PRC1.1 insufficiency on myelofibrosis. Transcriptome and chromatin immunoprecipitation sequence analysis showed the de-repression of PRC1.1 target genes in Pcgf1-deficient JAK2V617F hematopoietic progenitors and revealed Hoxa cluster genes as direct targets.
    [Leukemia]

    Abstract

    Multipotent Progenitors and Hematopoietic Stem Cells Arise Independently from Hemogenic Endothelium in the Mouse Embryo

    Scientists demonstrated by clonal assays and single-cell transcriptomics that rare hemogenic endothelium (HE) with functional HSC potential in the early murine embryo were distinct from more abundant HE with multilineage hematopoietic potential that failed to generate HSCs.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Definitive Hematopoietic Stem Cells Minimally Contribute to Embryonic Hematopoiesis

    Using single-cell transcriptomics, investigators defined gene signatures that distinguished nascent HSCs from embryonic blood progenitors. Applying a lineage-tracing approach to selectively track HSC output in situ, they found significantly delayed lymphomyeloid contribution.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Efficacy of Venetoclax plus Rituximab for Relapsed CLL: 5-Year Follow-Up of Continuous or Limited- Duration Therapy

    The authors reported long-term follow-up of the Phase Ib study of venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy.
    [Blood]

    Full Article

    Graphical Abstract

    Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase Ib Results from the JAVELIN Hodgkins Trial

    Avelumab was tolerable and demonstrated antitumor activity in heavily pretreated patients with classical Hodgkin lymphoma (cHL), suggesting that PD-L1 blockade may be sufficient for therapeutic benefit in cHL.
    [Blood Advances]

    Full ArticleGraphical Abstract

    Bortezomib and Rituximab in De Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre-B-Cell Acute Lymphoblastic Leukemia

    Researchers conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20+, Philadelphia-negative precursor B-ALL; bone marrow measurable residual disease negativity at the end of induction was the primary end point.
    [Blood Advances]

    Full ArticleGraphical Abstract

    Image of man completing the on-demand CFU assay course on his laptop.
    REVIEWS

    Understanding and Overcoming Adverse Consequences of Genome Editing on Hematopoietic Stem and Progenitor Cells

    The authors summarize the status of hematopoietic stem and progenitor cell (HSPC) gene editing, focusing on efficiency, genomic integrity, and long-term engraftment ability related to available genetic editing platforms and HSPC delivery methods.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Clinical and Biological Aspects of Myeloid Leukemia in Down Syndrome

    Despite advances in understanding the clinical and biological aspects of myeloid leukemia in children with Down syndrome (DS), little is known about the mechanisms of relapse. Upon relapse, patients face a poor outcome, and there is no consensus on treatment. Future studies need to be focused on this challenging aspect of leukemia in children with DS.
    [Leukemia]

    Abstract

    Therapeutic Targeting of the Inflammasome in Myeloid Malignancies

    Investigators discuss the role and importance of inflammasomes and immune pathways in myeloid malignancies, particularly myelodysplastic syndromes/acute myeloid leukemia, to better understand the disease pathophysiology and decipher the scope of therapeutic interventions.
    [Blood Cancer Journal]

    Full Article

    INDUSTRY AND POLICY NEWS

    EdiGene
    Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of Its Investigational Gene-Editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent β-Thalassemia

    EdiGene, Inc. announced the first patient enrolled in multicenter Phase I clinical study of its investigational gene-editing hematopoietic stem cell therapy ET-01 for patients with transfusion dependent β-thalassemia at the Institute of Hematology and Blood Diseases Hospital.
    [EdiGene, Inc. (Business Wire, Inc.)]

    Press Release

    Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-Related Myelodysplastic Syndromes

    Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent prior to allogeneic transplant in patients with GATA2-related myelodysplastic syndromes.
    [Jasper Therapeutics, Inc. (Business Wire, Inc.)]

    Press Release

    VOR33 Granted US FDA Fast Track Designation for AML

    Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, the company’s lead engineered HSC therapeutic candidate for the treatment of acute myeloid leukemia (AML).
    [Vor Biopharma]

    Press Release

    New Grant Awarded to MSK for Efforts in Acute Myeloid Leukemia Research

    Memorial Sloan Kettering Cancer Center has received a major grant from the US National Institutes of Health to conduct research related to leukemia.
    [Memorial Sloan Kettering Cancer Center]

    Press Release

    FEATURED EVENT

    6th World Congress of the Tissue Engineering and Regenerative Medicine International Society

    November 15 – 19, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Cancer Biology

    Houston Methodist Research Institute – Houston, Texas, United States

    PhD Student – Tumor Immunology

    University Hospital of Bern – Bern, Switzerland

    Advanced Practice Provider – Stem Cell Transplantation

    Banner MD Anderson Cancer Center – Gilbert, Arizona, United States

    Postdoctoral Fellow – Hematopoietic and Mesenchymal Cells

    Lund University – Lund, Sweden

    Faculty Positions – Cancer Research

    Sidney Kimmel Cancer Center at Jefferson Health – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter